KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, Phase 3 clinical trial.

Masaki Kato, Kazuyuki Nakagome, Takamichi Baba, Takuhiro Sonoyama, Hiroki Fukuju, Ryosuke Shimizu, Juan Carlos Gomez, Tomoko Motomiya, Takeshi Inoue

Psychiatry Clin Neurosci 80(1) 76-86

PMID41251319
PMCIDPMC12757765
DOI10.1111/pcn.13917
发表日期2025-11-18
入排依据:未发现恶性肿瘤人群证据。
已检查 5 张 PubMed Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:CONSORT/入组流程图;Fig. 3:AI 判定为 other;Fig. 4:AI 判定为 other;Fig. 5:AI 判定为 other。
摘要

摘要

AIM: To evaluate the efficacy and safety of oral zuranolone for 14 days, compared with placebo, in Japanese patients with major depressive disorder (MDD). METHODS: This multicenter, Phase 3 study was conducted in two parts (70 sites; Japan) including a randomized, double-blind, placebo-controlled, parallel-group part presented herein. Participants aged 18-75 years with the 17-item Hamilton Rating Scale for Depression (HAMD-17) total score ≥ 22 were randomized (1:1) ratio to receive either zuranolone (30 mg once daily) or placebo for 14 days with follow-up on Days 3, 8, and 15 and then weekly for 6 weeks (57 days) thereafter. The primary endpoint was change from baseline in the HAMD-17 total score at Day 15. RESULTS: Overall, 412 participants were randomized to receive either zuranolone 30 mg (n = 207) or placebo (n = 205). The difference in the least-squares mean (95% confidence interval [CI]) change from baseline in the HAMD-17 total score between groups (-1.20; 95% CI: -2.32, -0.08; P = 0.0365) was statistically significant on Day 15. A significant improvement in the HAMD-17 total score was observed with zuranolone 30 mg during the early treatment period on Days 3 and 8 compared with placebo; however, no significant differences were observed between the groups at later time points, from Day 22 to Day 57. The frequency of adverse events was higher in the zuranolone group (55.1%) than in the placebo group (40.7%); however, no serious adverse events were reported. CONCLUSION: Zuranolone improved depressive symptoms on Day 15, compared with placebo, in Japanese patients with MDD. No new safety signals were observed. CLINICAL TRIAL REGISTRATION: jRCT2031210577.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Study design. a Patients were stratified at randomization according to sex, the HAMD‐17 total score at baseline (> 22 to ≤ 24 vs . ≥ 25), and the presence or absence of prior treatment for the current depressive episode. b Primary endpoint: Change from baseline in the HAMD‐17 total score. Abbreviation: HAMD‐17, 17‐item Hamilton Rating Scale for Depression.
非 KM Figure
Fig. 2Fig. 2 CONSORT flow chart. Abbreviations: CONSORT, Consolidated Standards of Reporting Trials; GCP, good clinical practice; HAMD‐17, 17‐item Hamilton Rating Scale for Depression.
非 KM Figure
Fig. 3Fig. 3 Least‐squares mean (SE) change from baseline in the HAMD‐17 total score over 57 days (full analysis set) in the zuranolone 30 mg group compared with the placebo group. MMRM with an unstructured covariance structure was applied to estimate study intervention difference between the zuranolone 30 mg and placebo groups. Fixed‐effects: treatment group, time point, and interaction effect (treatment group and time point). Covariates: baseline value of the HAMD‐17 total score, sex, and presence or absence of prior drug for depressive episodes. * P < 0.05. Abbreviations: CI, confidence interval; HAMD‐17, 17‐item Hamilton Rating Scale for Depression; MMRM, mixed‐effects model for repeated measures; SE, standard error.
非 KM Figure
Fig. 4Fig. 4 Bar graph of (A) response and (B) remission by the HAMD‐17 score over 57 days (full analysis set). * P < 0.05. IPW‐GEE analysis. IPW‐GEE with an independent structure for the working correlation matrix was applied to estimate study intervention differences between the zuranolone 30 mg and placebo groups. Fixed‐effects: treatment group, time point, and interaction effect (treatment group and time point). Covariates: baseline value of the HAMD‐17 total score, sex, and presence or absence of prior drug for depressive episodes. * P < 0.05. Response: The number of patients with nonmissing HAMD‐17 total scores at the visit and at baseline was evaluated. The number of patients with a response was defined as a ≥ 50% reduction in the baseline HAMD‐17 total score. The denominator of the percentage is the number of patients with nonmissing HAMD‐17 total score at the visit and at baseline. Remission: The number of patients with nonmissing HAMD‐17 total scores at the visit was evaluated. The number of patients with remission was defined as a HAMD‐17 score ≤ 7. The denominator of the percentage was the number of patients with nonmissing HAMD‐17 total score at the visit. In the analysis of remission, data on Day 3 were excluded from the IPW‐GEE model to avoid nonconvergence. Abbreviations: CI, confidence interval; HAMD‐17, 17‐item Hamilton Rating Scale for Depression; IPW‐GEE, inverse probability‐weighted generalized estimating equation.
非 KM Figure
Fig. 5Fig. 5 Scatter plot of plasma concentration (ng/mL) of zuranolone 30 mg on Day 8 (Visit 3) and Day 15 (Visit 4).
非 KM Figure